Curevac announces financial results for the first quarter of 2025 and provides business updates

U.s. fda clears lung cancer ind for cvhnlc, a proprietary off-the-shelf candidate targeting squamous non-small cell lung cancer (sqnclc), with clinical study expected to begin h2 2025; clinical trial application filed in europe with decision expected in q2 2025 glioblastoma study fully enrolled with part b of phase 1 cvgbm trial completing enrolment in q1 2025; go/no-go decision on moving to phase 2 planned for h2 2025 first urinary tract infection vaccine moving forward with u.s. ind filing planned for h2 2025 core mrna patents upheld as european patent office confirmed validity of two key patents in amended form; infringement hearing against biontech/pfizer before the regional court dÜsseldorf set for july 1, 2025 strong cash and cash equivalents position of €438.3 million as of march 31, 2025; reaffirming expected cash runway into 2028 tÜbingen, germany and boston, ma / access newswire / may 20, 2025 / curevac n.v. (nasdaq:cvac), a pioneering multinational biotech company developing a new class of transformative medicines based on messenger rna (mrna), today announced financial results for the first quarter of 2025 and provided a business update.
CVAC Ratings Summary
CVAC Quant Ranking